Strategic partnerships GB Sciences is actively pursuing licensing and collaboration opportunities, evidenced by the July 2024 LOI with Endopure Life Sciences to commercialize cannabinoid-based treatments in Brazil and South America. This signals openness to channel partnerships and regional distribution deals that sales teams can leverage.

Plant-based leadership The company markets a proprietary AI powered platform (PhAROS) for plant-inspired drug discovery with a focus on multi-plant mixtures and traditional medical systems. This positions GB Sciences to offer co-development or licensing of novel formulations to big pharma players seeking differentiated, plant-derived drug candidates.

Clinical readiness With five late preclinical programs and a Parkinson’s disease lead prepared for First-in-Man trials, there are near-term opportunities for strategic collaborations around Phase 1/2 trials, CRO partnerships, and potential co-funding from interested biopharma or specialty pharma groups.

Global IP moat Having a substantial patent estate (issued and pending across 28 and 25 formulas respectively) provides a strong competitive barrier. Sales conversations can emphasize licensing visibility, co-development rights, and regional exclusivity to potential partners.

Diverse market appeal GB Sciences targets high-value indications including Parkinson’s disease, chronic pain, inflammation and heart-related disorders, offering multiple entry points for partnerships across neuroscience, cardiology, and pain management segments, as well as cross-border commercialization opportunities.